152 related articles for article (PubMed ID: 23359430)
21. Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients.
Iurlo A; Ubertis A; Artuso S; Bucelli C; Radice T; Zappa M; Cattaneo D; Mari D; Cortelezzi A
Eur J Intern Med; 2014 Jan; 25(1):63-6. PubMed ID: 24309387
[TBL] [Abstract][Full Text] [Related]
22. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Gotta V; Widmer N; Decosterd LA; Chalandon Y; Heim D; Gregor M; Benz R; Leoncini-Franscini L; Baerlocher GM; Duchosal MA; Csajka C; Buclin T
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1307-19. PubMed ID: 25297989
[TBL] [Abstract][Full Text] [Related]
23. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
24. Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome.
Le Coutre P; Kreuzer KA; Na IK; Schwarz M; Lupberger J; Holdhoff M; Baskaynak G; Gschaidmeier H; Platzbecker U; Ehninger G; Prejzner W; Huhn D; Schmidt CA
Am J Hematol; 2003 Aug; 73(4):249-55. PubMed ID: 12879428
[TBL] [Abstract][Full Text] [Related]
25. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
26. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
[TBL] [Abstract][Full Text] [Related]
27. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.
Efficace F; Rosti G; Cottone F; Breccia M; Castagnetti F; Iurlo A; Mandelli F; Baccarani M
Leuk Res; 2014 Mar; 38(3):294-8. PubMed ID: 23906625
[TBL] [Abstract][Full Text] [Related]
28. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
29. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
30. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
Qin YZ; Liu YR; Li JL; Ruan GR; Zhu HH; Jiang Q; Fu JY; Lu Y; Chang Y; Li LD; Huang XJ; Chen SS; Qiu JY
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3186-9. PubMed ID: 16405837
[TBL] [Abstract][Full Text] [Related]
32. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
Noens L; van Lierde MA; De Bock R; Verhoef G; Zachée P; Berneman Z; Martiat P; Mineur P; Van Eygen K; MacDonald K; De Geest S; Albrecht T; Abraham I
Blood; 2009 May; 113(22):5401-11. PubMed ID: 19349618
[TBL] [Abstract][Full Text] [Related]
33. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Bartley PA; Slader C; Field C; Dang P; Filshie RJ; Mills AK; Grigg AP; Melo JV; Hughes TP
Leukemia; 2010 Oct; 24(10):1719-24. PubMed ID: 20811403
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
35. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients].
Zhou L; Wang AH; Wang L; You JH; Li JM; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):13-7. PubMed ID: 18512309
[TBL] [Abstract][Full Text] [Related]
37. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
38. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
39. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Tauchi T; Kizaki M; Okamoto S; Tanaka H; Tanimoto M; Inokuchi K; Murayama T; Saburi Y; Hino M; Tsudo M; Shimomura T; Isobe Y; Oshimi K; Dan K; Ohyashiki K; Ikeda Y;
Leuk Res; 2011 May; 35(5):585-90. PubMed ID: 21145591
[TBL] [Abstract][Full Text] [Related]
40. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
